Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / The 4th China Intl Import Expo

    Top executives weigh in at CIIE (IV)

    chinadaily.com.cn | Updated: 2021-11-11 06:40
    Share
    Share - WeChat

    Anna Van Acker, president of MSD in China

    A1: On our third year, leveraging CIIE's unique platform, we enhance communication, sharing, and jointly respond to global public health threats with Chinese partners. Showcase our extensive products, R&D pipeline, innovative medical solutions, and our long-term commitment to benefiting Chinese patients and customers. China has always been a key market for MSD. Adhering to our mission of "Inventing for Life", we continuously bring more innovative and life-saving drugs as well as advanced vaccines to China to better benefit Chinese patients and the public, and support to achieve the "Healthy China 2030" initiative.

    A2: The CIIE provides impetus to the recovery of international exchange, providing opportunities and communication platforms for the multinational companies in China across industries. With the pandemic, global attention to vaccines and infectious disease prevention and control has been much higher than before. As a global leader in the vaccine industry, MSD will continue fulfilling our commitment by promoting innovation and improving medicine accessibility and affordability to benefit Chinese patients and consumers. At this year's CIIE, MSD introduce the first oral antiviral drug, Molnupiravir, if approved by FDA.

    A3: MSD welcomes China's efforts in accelerating the review and approval of innovative medicines and vaccines to benefit Chinese patients. For example, National Medical Product Administration has installed a fast-track review mechanism. CIIE itself serves as an epitome of China's efforts to improve import, which allows all the players to showcase their most innovative products across different industries.

    A4: With health being a main subject of attention today, MSD is pleased to see the recent rapid development of China's pharmaceutical industry regarding R&D talent, scientific research capabilities, investments, business and policy environment.

    As an active participant and builder of the China's health market, MSD is thrilled to join a more mature and diversified consumer market today, which is conducive to the long-term development of MSD in China. Together with local partners, we will bring more vaccines and health solutions to benefit more Chinese consumers for the improvement of public health in China.

    A5: China's reform and opening-up has achieved remarkable results, as recognized by the international community. For example, a lot of efforts have been made in improving the business environment of the pharmaceutical industry, which allows companies to introduce life-saving medicines and innovative vaccines to China at a faster rate. We look forward to higher-level opening-up to facilitate the realization of "Healthy China 2030."

    The continuous optimization of China's business environment has strengthened our confidence in the sustainable development of MSD in China. We will seize the opportunities and continue to work with the government, the institutions and our business partners to meet the unmet medical needs of Chinese patients and the public.

    A6: China's opening-up has optimized the business environment and attracted players around the world. At the same time, more Chinese enterprises are branching out, which contributed to increased flow of ideas, talent and a more diverse business ecosystem.

    A8: Compared with some other countries, how does China's firm support for free trade and multilateralism fare?

    The world has been facing common health challenges that require all stakeholders to come together and work out tangible solutions. Encouragement of collaborations will be conducive to saving and improving lives around the world.

    |<< Previous 1 2 3 4 5 6 7 8 9 10 11 Next   >>|
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    亚洲成A人片在线观看无码不卡 | 欧美乱人伦中文字幕在线| 在线免费中文字幕| 国产高清无码二区| 亚洲AV中文无码乱人伦下载| 亚洲天堂中文资源| 亚洲高清有码中文字| 精品久久久久久无码专区| 无码国产精品一区二区免费虚拟VR| 中文字幕亚洲欧美日韩在线不卡 | 国产在线拍偷自揄拍无码| 丝袜无码一区二区三区| 91在线中文字幕| 伊人久久一区二区三区无码| 18禁免费无码无遮挡不卡网站 | 欧洲成人午夜精品无码区久久| 无码乱肉视频免费大全合集| 欧美一级一区二区中文字幕 | 亚洲中文字幕无码一区二区三区| 国产亚洲精久久久久久无码AV| 日韩免费人妻AV无码专区蜜桃| 国产啪亚洲国产精品无码| 精品久久久久久久久久中文字幕| 人妻丰满av无码中文字幕| 中文字幕一区二区人妻性色| 无码精品人妻一区二区三区免费| 国产精品午夜无码AV天美传媒 | 一级片无码中文字幕乱伦| 久久精品无码一区二区三区免费| 少妇人妻偷人精品无码视频| 未满十八18禁止免费无码网站 | 2021无码最新国产在线观看| 高清无码在线视频| 成人无码区在线观看| 国产成人无码免费看片软件| 国产免费久久久久久无码| 成?∨人片在线观看无码| 亚洲精品无码av天堂| 伊人久久无码精品中文字幕| 日韩精品中文字幕无码一区| 最近免费中文字幕mv在线电影 |